Allscripts, Demand Media, Gilead, Idenix, Netspend: U.S. Equity Movers

Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.

Allscripts Healthcare Solutions Inc. (MDRX) fell the second-most in the Russell 1000 Index, sliding 9 percent to $19.54. The software maker said it sees profit this year of no more than $1.10 a share, missing the average analyst estimate of $1.11.

Arthrocare Corp. (ARTC) fell the most in the Russell 2000 Index, dropping 19 percent to $25. The surgical-tool maker reported fourth-quarter sales that missed analysts’ estimates. Jefferies Group Inc. cut the stock’s rating to hold from buy.

Cell Therapeutics Inc. (CTIC) surged 22 percent to $1.35 for the fourth-biggest increase in the Russell 2000 Index. The European Medicines Agency recommended conditional approval of the company’s Pixuvri treatment for the cancer non-Hodgkin’s B- cell lymphoma.

Demand Media Inc. (DMD) (DMD US) rallied 31 percent to $7.76 for the biggest gain in the Russell 2000. The online operator of websites eHow.com and LiveStrong.com reported fourth-quarter adjusted profit that topped analysts’ estimates.

First Solar Inc. (FSLR) rose 7.3 percent to $42.59 for the biggest gain in the Standard & Poor’s 500 Index. The biggest maker of thin-film solar panels resolved a permitting issue with Los Angeles County for a $1.36 billion power project under construction, paving the way for financing to resume.

FreightCar America Inc. (RAIL) gained 19 percent, the most since July 2005, to $25.33. The maker of railroad freight cars reported fourth-quarter revenue of $187.1 million, beating the average analyst estimate of $128 million.

General Mills Inc. (GIS) fell 3.6 percent, the most since July 2010, to $38.34. The maker of Cheerios and Green Giant frozen vegetables cut its full-year earnings forecast to $2.55 per share at most after previously seeing as much as $2.61. The projection misses the average analyst estimate of $2.60.

Gilead Sciences Inc. (GILD) dropped 14 percent, the most in the S&P 500, to $47. The Foster City, California-based biopharmaceutical company said six out of eight participants in a study using its experimental hepatitis C drug showed “viral relapse” within four weeks after stopping a 12-week treatment plan.

Rivals rallied. Vertex Pharmaceuticals Inc. (VRTX) rose 4.7 percent to $39.24. Achillion Pharmaceuticals Inc. (ACHN) jumped 26 percent to $11.04. Idenix Pharmaceuticals Inc. (IDIX) climbed 3.9 percent to $11.91.

H.J. Heinz Co. (HNZ) rose 4.6 percent, the most since September 2009, to $54.47. The world’s biggest ketchup maker reported third-quarter adjusted earnings of 95 cents per share, beating the average estimate of 85 cents per share. Third- quarter sales of $2.92 billion also beat the average estimate of $2.89 billion.

Life Technologies Corp. (LIFE) fell 7.8 percent to $45.92, the second-biggest loss in the S&P 500. The provider of gene-analysis tools will face competition from Oxford Nanopore Technologies Ltd., which is entering the gene-sequencing race with a new portable device that will allow people to analyze DNA on the go. The market is also led by Illumina Inc. (ILMN) , which fell 3.9 percent to $51.82.

Maxwell Technologies Inc. (MXWL) fell 5.3 percent, the most since Nov. 9, to $19.93. The maker of electronic components declined as Robert W Baird & Co. shifted the company to “neutral” from “outperform,” based on lower-than-expected fourth-quarter revenue.

Netspend Holdings Inc. (NTSP) rose 13 percent to $9.50, the highest price since July 8. The Austin, Texas-based provider of reloadable prepaid debit cards forecast earnings of as much as 55 cents a share this year, above the average analyst estimate of 52 cents.

RealPage Inc. (RP) slumped 14 percent, the most since it went public in August 2010, to $20.71. The provider of rental- property management software forecast first-quarter profit excluding some items of 10 cents a share, trailing the 11-cent average analyst estimate in a Bloomberg survey.

SunPower Corp. (SPWR) (SPWR US) rose 8.7 percent, the second-most in the Russell 1000, to $8.13. The solar panel company majority- owned by Total SA reported better-than-estimated fourth-quarter earnings and said 2012 sales will be in line with previous forecast.

To contact the reporter on this story: Katia Porzecanski in New York at kporzecansk1@bloomberg.net

To contact the editor responsible for this story: Nick Baker at nbaker7@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.